RxDoctor Payments Data

Andrew Kwa, MD

Interventional Cardiology · San Jose, CANPI 1821013889

Payments from drug & device makers

$90,606in general payments, 2019–2025

Across 1,128 payments — averaging $80.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$27K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Abbott$9K
  • Pfizer$6K
  • Philips North America LLC$5K
  • Biotronik Inc.$3K
  • plus $24K from 51 others

What the payments were for

  • Consulting fees$1,4632%
  • Speaking & faculty fees$41,58746%
  • Travel & lodging$2,5233%
  • Food & beverage$44,83749%
  • Education$1960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,606 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$847,037
Medicare patients
1,062
Services billed
9,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban532$775,763
XareltoRivaroxaban103$153,922
Repatha SureclickEvolocumab148$131,854
EntrestoSacubitril/Valsartan77$102,460
FarxigaDapagliflozin Propanediol46$56,973
MultaqDronedarone Hcl28$43,232
BrilintaTicagrelor40$39,494
VascepaIcosapent Ethyl22$18,254
LivaloPitavastatin Calcium14$13,501
Metoprolol Succinate766$11,663
Flecainide Acetate163$9,007
Diltiazem 24hr Er (Cd)Diltiazem Hcl85$5,956
Atorvastatin Calcium479$5,835
Losartan Potassium443$5,677
Rosuvastatin Calcium267$4,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6,471$775,763532 claims
Johnson & JohnsonXarelto$1,056$153,922103 claims
NovartisEntresto$2,295$102,46077 claims
AstraZenecaFarxiga, Brilinta$1,192$96,46786 claims
Sanofi-aventis U.S. LLCMultaq$264$43,23228 claims
Kowa Pharmaceuticals America, Inc.Livalo$289$13,50114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →